Blood biomarkers for triple negative breast cancer karen s anderson md phd o caution for use within the first 4 6 weeks of therapy from harris et al j clinoncol 2007 diagnosis staging or routine surveillance of patients after primary therapy o there is an emerging set of blood biomarkers for cancer that have potential for . Keywords biomarkers targeted therapy triple negative breast cancer introduction breast cancer is well characterized as a heterogeneous disease composed of discrete biologic subtypes which guide clinical management peppercorn et al 2008 . Triple negative breast cancer tnbc is a heterogeneous disease with different biological characteristics and treatment outcomes compared to other subtypes of breast cancer recently platinum based chemotherapy has received increased attention in tnbcs based on promising results especially in the . Triple negative breast cancer is one the most frequently diagnosed and major causes of cancer deaths among young women generally mammography is used to detect breast cancer at an early stage. Triple negative breast cancer tnbc comprises 15 20 percent of all breast cancers but few treatment options exist outside of chemotherapy this aggressive form of breast cancer disproportionately affects young women as well as women of african descent and is the most commonly diagnosed breast cancer in women with brca1 mutations
How it works:
1. Register a Free 1 month Trial Account.
2. Download as many books as you like ( Personal use )
3. No Commitment. Cancel anytime.
4. Join Over 100.000 Happy Readers.
5. That's it. What you waiting for? Sign Up and Get Your Books.